My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Evolus, Inc. - Common Stock
(NQ:
EOLS
)
5.980
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 25, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Evolus, Inc. - Common Stock
< Previous
1
2
3
4
Next >
What's going on in today's session
August 06, 2025
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
August 06, 2025
Via
Benzinga
Here are the top movers in Wednesday's session.
August 06, 2025
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Via
Chartmill
Earnings Scheduled For August 5, 2025
August 05, 2025
Via
Benzinga
A Look Ahead: Evolus's Earnings Forecast
August 04, 2025
Via
Benzinga
Earnings Scheduled For May 7, 2025
May 07, 2025
Via
Benzinga
Assessing Evolus: Insights From 6 Financial Analysts
March 05, 2025
Via
Benzinga
Breaking Down Evolus: 4 Analysts Share Their Views
February 14, 2025
Via
Benzinga
The market is filled with gapping stocks in Wednesday's session.
August 06, 2025
Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps.
Via
Chartmill
Evolus (EOLS) Q2 Revenue Rises 4%
August 06, 2025
Via
The Motley Fool
Topics
Economy
Discover the top movers in Wednesday's pre-market session.
August 06, 2025
The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via
Chartmill
Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
August 06, 2025
Via
Benzinga
4 Analysts Have This To Say About Evolus
January 22, 2025
Via
Benzinga
A Closer Look at 5 Analyst Recommendations For Evolus
October 03, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
August 06, 2025
Via
Benzinga
Why Astera Labs Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
August 06, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
August 05, 2025
Via
Benzinga
Top movers in Tuesday's after hours session
August 05, 2025
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Via
Chartmill
Analyst Scoreboard: 4 Ratings For Evolus
September 13, 2024
Via
Benzinga
What Analysts Are Saying About Evolus Stock
May 08, 2025
Via
Benzinga
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
April 17, 2025
Via
Benzinga
Breaking Down Evolus: 8 Analysts Share Their Views
April 09, 2025
Via
Benzinga
Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas
March 10, 2025
There's a lot going on for investors.
Via
The Motley Fool
Nasdaq Jumps 100 Points; Charles Schwab Profit Beats Estimates
January 21, 2025
Via
Benzinga
Earnings Scheduled For March 4, 2025
March 04, 2025
Via
Benzinga
Crude Oil Down 2%; D.R. Horton Earnings Top Views
January 21, 2025
Via
Benzinga
Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why
January 21, 2025
The company expects to soon expand from a single-product player to a "multi-product innovator."
Via
Investor's Business Daily
Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday
January 21, 2025
Via
Benzinga
EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q2 2024
July 31, 2024
EOLS stock results show that Evolus missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early
July 31, 2024
The company reported $1.1 million in adjusted operating income, well ahead of expectations for a $2.6 million loss.
Via
Investor's Business Daily
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.